These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 25009051)
1. Whether the use of unopposed oestrogen following a myocardial infarction is beneficial or harmful remains unclear, and in individual women the effects may vary according to the underlying risk profile. Shapiro S Evid Based Med; 2014 Oct; 19(5):195. PubMed ID: 25009051 [No Abstract] [Full Text] [Related]
2. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. Cherry N; McNamee R; Heagerty A; Kitchener H; Hannaford P BJOG; 2014 May; 121(6):700-5; discussion 705. PubMed ID: 24533510 [TBL] [Abstract][Full Text] [Related]
3. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Beresford SA; Weiss NS; Voigt LF; McKnight B Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575 [TBL] [Abstract][Full Text] [Related]
9. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Shields TS; Weiss NS; Voigt LF; Beresford SA Epidemiology; 1999 Nov; 10(6):733-8. PubMed ID: 10535788 [TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829 [TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Beral V; Bull D; Reeves G; Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308 [TBL] [Abstract][Full Text] [Related]
13. [Hormone replacement therapy--treatment with risk factors]. Greiser E Dtsch Med Wochenschr; 2001 Mar; 126(9):255-6. PubMed ID: 11256042 [No Abstract] [Full Text] [Related]
14. [Hormone replacement therapy in the climacteric]. Canto de Cetina TE Rev Invest Clin; 1995; 47(1):49-61. PubMed ID: 7777716 [TBL] [Abstract][Full Text] [Related]
15. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Psaty BM; Heckbert SR; Atkins D; Lemaitre R; Koepsell TD; Wahl PW; Siscovick DS; Wagner EH Arch Intern Med; 1994 Jun; 154(12):1333-9. PubMed ID: 8002685 [TBL] [Abstract][Full Text] [Related]
16. Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study. Carrasquilla GD; Berglund A; Gigante B; Landgren BM; de Faire U; Hallqvist J; Leander K Menopause; 2015 Jun; 22(6):598-606. PubMed ID: 25490112 [TBL] [Abstract][Full Text] [Related]
17. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Heckbert SR; Weiss NS; Koepsell TD; Lemaitre RN; Smith NL; Siscovick DS; Lin D; Psaty BM Arch Intern Med; 1997 Jun; 157(12):1330-6. PubMed ID: 9201007 [TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251 [TBL] [Abstract][Full Text] [Related]
20. Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Whittington R; Faulds D Pharmacoeconomics; 1994 Jun; 5(6):513-54. PubMed ID: 10147266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]